Updated:
Noetic Fund
Noetic is a venture firm investing in early-stage technologies that address mental health and wellbeing. Its diversified, multi-modal strategy spans novel drug...
Noetic Fund
Noetic is a venture firm investing in early-stage technologies that address mental health and wellbeing. Its diversified, multi-modal strategy spans novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, wearables and other evidence-backed solutions, with a global outlook. The firm focuses on treatments that target root causes of illness and emphasize early intervention and prevention, including CNS-targeted therapeutics and related sustainable solutions for mental health and physical well being.
General information
Firm type
Private Equity
Year founded
2020
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Toronto, Canada
Principals
Sa'ad Shah
Managing Partner
Warren Wright
Managing Partner
Sri Teja Mullapudi
Principal, Fund Investments, Scientific Lead
Richard Cheung
General Counsel
Sector focus
Frequently asked questions
Who runs investment decisions at Noetic Fund?
Managing Partners Sa’ad Shah and Warren Wright lead investment decisions, supported by Principal and Scientific Lead Sri Teja Mullapudi. Both Shah and Wright spent over a decade at DGAM, the asset management firm acquired by The Carlyle Group, where Wright served as CIO of Carlyle Liquid Markets Group. The small senior team structure ensures that every investment passes through operators who previously managed multi-billion-dollar institutional portfolios.
How does Noetic source proprietary deal flow in psychedelics and mental health?
Noetic’s sourcing blends deep scientific networks with operator referrals. Principal Sri Teja Mullapudi maintains ties to academic research institutions through his doctoral work at the Max Planck Society, while Venture Partner Jeffrey Becker, a practicing psychiatrist, provides clinical-trial visibility and patient-need signals. The firm’s early bets on now-public companies like COMPASS Pathways and MindMed have also created a referral cycle from exited founders and clinical collaborators.
Does Noetic participate in fund commitments or only direct deals?
The firm makes direct equity investments in startups, predominantly at the seed and early-stage phases. Publicly disclosed holdings such as Cybin, COMPASS Pathways, Delix Therapeutics, and Beckley Psytech are all direct company stakes. There is no public evidence of a fund-of-funds or LP-commitment program.
What investment stages does Noetic Fund typically target?
Noetic focuses on seed, start-up, and early-stage growth rounds, often providing first institutional capital to preclinical or Phase I CNS companies. Its dual-fund structure allows for follow-on investments as portfolio companies advance through clinical milestones. The firm’s website describes a strategy spanning emerging and early-stage wellness and pharmaceutical enterprises.
Which sectors does Noetic explicitly avoid?
Noetic’s mandate is explicitly concentrated on mental health and CNS-targeted therapeutics with related wellness applications. The firm does not invest in general digital health, oncology, metabolic disease, or medical device sectors outside its mental-health and wellbeing thesis. Its website limits focus to drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, wearables, and evidence-backed wellness solutions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: